FDA and European Medicines Agency accept applications for shorter 2-hour infusion time for ocrelizumab

The regulatory applications are based on data from ENSEMBLE PLUS study, which showed comparable frequency and severity of infusion-related reactions for a two-hour infusion time vs. the currently approved 3.5-hour time in patients with relapsing-remitting MS.


Biospace Inc.